Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
As the population ages, more elderly patients require radiotherapy-based treatment for their pelvic malignancies, including muscle-invasive bladder cancer, as they are unfit for major surgery. Therefore, there is an urgent need to find radiosensitising agents minimally toxic to normal tissues, inclu...
Main Authors: | Groselj, B, Ruan, J, Scott, H, Gorrill, J, Nicholson, J, Kelly, J, Anbalagan, S, Thompson, J, Stratford, M, Jevons, S, Hammond, E, Scudamore, C, Kerr, M, Kiltie, A |
---|---|
Format: | Journal article |
Published: |
American Association for Cancer Research
2017
|
Similar Items
-
Radiosensitation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
by: Groselj, B, et al.
Published: (2017) -
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
by: Groselj, B, et al.
Published: (2013) -
Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair
by: Groselj, B, et al.
Published: (2013) -
The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
by: Paillas, S, et al.
Published: (2020) -
The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer
by: Groselj, B
Published: (2014)